Europe's drug regulator starts safety review of anemia drugs

04/28/2007 | MarketWatch

The European Medicines Agency says it is reviewing anemia drugs from Amgen, Roche Holding and Shire PLC to see if they increase the risk of heart and cancer problems. In the meantime, the agency recommended confining the drugs to their indicated use, for treating anemia. The agency says it also is cooperating on a review of Johnson & Johnson's Eprex, sold as Procrit in the U.S.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX